Table 2.

Effects of icosapent ethyl vs. placebo on various biomarkers in REDUCE-IT⁴⁰

Biomarker a	Icosapent ethyl (N = 4089)		Placebo (N = 4090)		Median between-group difference at Year 1
	Median		Median
	Baseline	Year 1	Baseline	Year 1	Absolute change from baseline	% change from baseline	% change
							P-value
Triglycerides (mg/dL)	216.5	175.0	216.0	221.0	−44.5	−19.7	<0.001
Non-HDL-C (mg/dL)	118.0	113.0	118.5	130.0	−15.5	−13.1	<0.001
LDL-C (mg/dL)	74.0	77.0	76.0	84.0	−5.0	−6.6	<0.001
HDL-C (mg/dL)	40.0	39.0	40.0	42.0	−2.5	−6.3	<0.001
ApoB (mg/dL)	82.0	80.0	83.0	89.0	−8.0	−9.7	<0.001
hsCRP (mg/L)	2.2	1.8	2.1	2.8	−0.9	−39.9	<0.001
Log hsCRP (mg/L)	0.8	0.6	0.8	1.0	−0.4	−22.5	<0.001
EPA (µg/mL)	26.1	144.0	26.1	23.3	+114.9	+385.8	<0.001

^aApoB and hsCRP were measured at Year 2.